Follow
← Back
Medicines · Interactions

Spironolactone — interactions

Other medicines, foods and herbal products can change how Spironolactone works. Everything on this page comes from Spironolactone's own FDA-approved label — the same source as the main guide.

← Back to the full Spironolactone guide

⚠ Caution: • Agents increasing serum potassium: Concomitant administration can lead to hyperkalemia . • Lithium: Increased risk of lithium toxicity . • NSAIDs: May reduce the diuretic, natriuretic and antihypertensive effect of spironolactone . • Digoxin: Spironolactone can interfere with radioimmunologic assays of digoxin exposure . • Cholestyramine: Hyperkalemic metabolic acidosis has been reported with concomitant use .

Medicines named in Spironolactone's label

Grouped the way the label groups them. Each name links to that medicine's NepalDoc guide; where the label names a class instead of a medicine, the label's words are quoted.

Drugs and Supplements Increasing Serum Potassium

Concomitant administration of spironolactone with potassium supplementation or drugs that can increase potassium may lead to severe hyperkalemia. In general, discontinue potassium supplementation in heart failure patients who start spironolactone . Check serum potassium levels when ACE inhibitor or ARB therapy is altered in patients receiving spironolactone.

Lithium Like

Other diuretics, spironolactone reduces the renal clearance of lithium, thus increasing the risk of lithium toxicity. Monitor lithium levels periodically when spironolactone is coadministered .

Nonsteroidal Anti-Inflammatory

Drugs (NSAIDs) In some patients, the administration of an NSAID can reduce the diuretic, natriuretic, and antihypertensive effect of diuretics. Therefore, when spironolactone and NSAIDs are used concomitantly, monitor closely to determine if the desired effect of the diuretic is obtained .

Section 7.4 of the label

Digoxin Spironolactone and its metabolites interfere with radioimmunoassays for digoxin and increase the apparent exposure to digoxin. It is unknown to what extent, if any, spironolactone may increase actual digoxin exposure. In patients taking concomitant digoxin, use an assay that does not interact with spironolactone.

Cholestyramine Hyperkalemic

Metabolic acidosis has been reported in patients given spironolactone concurrently with cholestyramine.

Acetylsalicylic Acid

Acetylsalicylic acid may reduce the efficacy of spironolactone. Therefore, when spironolactone and acetylsalicylic acid are used concomitantly, spironolactone may need to be titrated to higher maintenance dose and the patient should be observed closely to determine if the desired effect is obtained .

Section 7.7 of the label

Abiraterone Spironolactone binds to the androgen receptor and may increase prostate-specific antigen (PSA) levels in abiraterone-treated prostate cancer patients. Concomitant use of spironolactone and abiraterone is not recommended.

Mitotane Avoid

Concomitant use of spironolactone and mitotane. Spironolactone reduces mitotane plasma levels .

Spironolactone's label names 3 medicines that NepalDoc also covers.

Their interaction pages

These medicines named in Spironolactone's label have interaction pages of their own:

Read the full interactions section from Spironolactone's label

• Agents increasing serum potassium: Concomitant administration can lead to hyperkalemia . • Lithium: Increased risk of lithium toxicity . • NSAIDs: May reduce the diuretic, natriuretic and antihypertensive effect of spironolactone . • Digoxin: Spironolactone can interfere with radioimmunologic assays of digoxin exposure . • Cholestyramine: Hyperkalemic metabolic acidosis has been reported with concomitant use . • Acetylsalicylic Acid (ASA): ASA may reduce the efficacy of spironolactone . • Abiraterone: May increase prostate-specific antigen (PSA) levels . • Mitotane: Avoid concomitant use of spironolactone and mitotane .

7.1 Drugs and Supplements Increasing Serum Potassium Concomitant administration of spironolactone with potassium supplementation or drugs that can increase potassium may lead to severe hyperkalemia. In general, discontinue potassium supplementation in heart failure patients who start spironolactone . Check serum potassium levels when ACE inhibitor or ARB therapy is altered in patients receiving spironolactone. Examples of drugs that can increase potassium include: • ACE inhibitors • angiotensin receptor blockers • non-steroidal anti-inflammatory drugs (NSAIDs) • heparin and low molecular weight heparin • trimethoprim

7.2 Lithium Like other diuretics, spironolactone reduces the renal clearance of lithium, thus increasing the risk of lithium toxicity. Monitor lithium levels periodically when spironolactone is coadministered .

7.3 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) In some patients, the administration of an NSAID can reduce the diuretic, natriuretic, and antihypertensive effect of diuretics. Therefore, when spironolactone and NSAIDs are used concomitantly, monitor closely to determine if the desired effect of the diuretic is obtained .

7.4 Digoxin Spironolactone and its metabolites interfere with radioimmunoassays for digoxin and increase the apparent exposure to digoxin. It is unknown to what extent, if any, spironolactone may increase actual digoxin exposure. In patients taking concomitant digoxin, use an assay that does not interact with spironolactone.

7.5 Cholestyramine Hyperkalemic metabolic acidosis has been reported in patients given spironolactone concurrently with cholestyramine.

7.6 Acetylsalicylic Acid Acetylsalicylic acid may reduce the efficacy of spironolactone. Therefore, when spironolactone and acetylsalicylic acid are used concomitantly, spironolactone may need to be titrated to higher maintenance dose and the patient should be observed closely to determine if the desired effect is obtained .

7.7 Abiraterone Spironolactone binds to the androgen receptor and may increase prostate-specific antigen (PSA) levels in abiraterone-treated prostate cancer patients. Concomitant use of spironolactone and abiraterone is not recommended.

7.8 Mitotane Avoid concomitant use of spironolactone and mitotane. Spironolactone reduces mitotane plasma levels .

Spironolactone guide · All interaction pages · Medicines A–Z

SourcesU.S. FDA-approved label via DailyMed (label effective 29 Dec 2025) · National List of Essential Medicines, Nepal (2021) · U.S. labeling may differ from Nepal DDA-approved labeling and local prescribing practice.

This page summarises Spironolactone's FDA-approved label for information — it is not medical advice. Always tell your doctor or pharmacist about every medicine, supplement and herbal product you take.

Search medicines in the app / एपमा औषधि खोज्नुहोस् Find a pharmacy / फार्मेसी खोज्नुहोस्
+ Safety information

This page is information only and is not medical advice. Medicine details come from the sources listed above and may change — always confirm the medicine, strength and dose with a pharmacist or doctor before use. NLEM listing does not guarantee that a medicine is in stock at any pharmacy.

Share this Medicine
NepalDoc — Nepal's Healthcare Super-App (Beta) / नेपालको स्वास्थ्य सुपर-एप (बेटा).
Medicine information only — not medical advice. Confirm with a pharmacist or doctor.